Introduction:We developed an algorithm-based mobile texting platform for promoting self-management in patients with interstitial cystitis/bladder pain syndrome (IC/BPS). Our aim was to measure the feasibility, usability, and potential utility of the …
The only urology-specific incubator of its kind, Innovation Nexus is a powerful forum for advanc ing urologic discovery to solutions that improve patient care and…
PDE5 inhibitors are the first-line medical treatment for ED, but up to 40% of patients do not have a satisfactory response to these agents.
The IDeate-Prostate01 trial plans to enroll approximately 1440 patients whose tumors progressed following prior treatment with an ARPI.
“Our findings support that that we do not drop the label of cancer from grade group 1 nomenclature,” says Jim C. Hu, MD, MPH.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
Margaret A. Knoedler, MD, discusses the advantages of using the MONARCH platform for mini-PCNL.
“Delegates can expect a scientific programme that balances andrological and reconstructive urological topics, and particularly where the two overlap,” says Dr. Marco Falcone (Turin, IT)…
Although spironolactone is very effective in patients that do not require dialysis, investigators tested whether spironolactone is effective in patients on dialysis in a phase…
The approval is supported by landmark results from the pivotal phase 2 SANS-UUI trial.
2023 Dues ($USD) $589 * $115 * $349, $314, $278 ◊ $150, $75, $50 ◊ $209 ^ $209 $209 $0 * Dues for Active/Associate members…
